Controlled Insanity

1:32 p.m., EST

It’s not ‘controlled opposition’

It’s controlled insanity

The masses (maybe all of us for that matter) have to be kept on edge just enough to be easily advanced to the next level of narrative.

Case in point, is this link.

It’s just one more piece of pre-programmed trash that’s attempting to control the public’s perception and direction.

“Globalists Losing Narrative”

Give me a break. Globalists aren’t losing anything. At least, not yet.

Markets & SPBIO

The overall markets are still hovering at all time highs; even as reports like this one, continue to show that everybody’s all-in on an unprecedented scale.

Evidently, they have no plan for down … where the real money’s made.

Moderna’s (MRNA) in its second day attempt to breakout higher; all the while, the index itself (SPBIO) continues to edge lower.

The 2-Hour chart of LABD below, shows a potential trend.

As with previous analysis comments, we’re looking for a trend the market itself, says is important:

It’s clear, the trend (above) has been repeated several times in LABD’s own price action.

LABD itself, tells us to pay attention.

The right side trend line might not look like much … but it’s rising at about +45,500%, on an annualized basis.

Positioning:

A break of this trend does not necessarily mean we’ll exit out Project Stimulus position; not advice, not a recommendation.

We’ve got the hard stop discussed previously at LABD 21.77; again, not advice, not a recommendation.

Summary:

While the retail traders/investors (the only direction they know is up) go collectively insane, we’re keeping under the radar and quietly maintaining the short positioning in biotech.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Lower, Lower … Weaker, Weaker

6:37 p.m., EST

Inverse biotech LABD, closes lower (again).

All is not what is seems.

Down-thrust energy diverging.

The daily close of LABD, shows price action has penetrated another (lower) support level.

Close below support on the weakest down-thrust energy (and lowest volume) since LABD, started its corrective move on May 14th.

Everyone has their own preferred time-frame. Ours is probably longer than most.

If there’s going to be a meltdown in biotech or some kind of serious correction lower, a likely bottom for a sustained move (as said before) will be where they usually are … the third week of October.

Price action is the final arbiter. However, it (SPBIO) has not (yet) indicated it’s on a new bull run to new highs.

At this point, the market’s frustrating both longs and shorts … and doing a good job of it as well.

Our short position via LABD, is being maintained … but the finger is edging closer to the sell button; not advice, not a recommendation.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Bulls Lose Their Footing

11:51 a.m., EST

The bulls upside attempt in biotech has failed

The last update said if biotech SPBIO, made a new daily high, the bulls would be gaining a foothold.

That new high and the foothold, have come and gone.

Admittedly, the retrace in SPBIO and inverse LABD went farther than anticipated.

However, as of this morning’s action, the attempt to move higher in biotech has either failed outright, or has been severely damaged.

If it’s failure, then we’re set up for a major downside move.

The daily chart of inverse LABD, has the now familiar trend-lines that are a repeating pattern.

The last two days may have formed yet another right side trend; rising at the same angle as the others on the chart.

There’s a remote chance, as price action nears SPBIO support (LABD near 30), the bulls could once again attempt to reverse course.

With the overall market oscillating to the downside (today’s counter move notwithstanding) and with biotech in the downside lead, an upside move seems unlikely.

The Project Stimulus position remains unchanged.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The ‘Gut Check’

9:09 a.m., EST

If there’s going to be a big move, the market will make sure you’re not along for the ride.

The proverbial ‘gut check’, as David Weis used to call it.

It’s an adverse move that’s intended to shake any (all, if possible) weak hands out of their positions.

How will we know if that’s what’s going on with biotech’s, SPBIO?

Yesterday, was an upside reversal bar on the daily SPBIO, chart. Will the market go higher (LABD, lower) from here?

The first clue will be the open.

If SPBIO opens lower, with inverse LABD opening higher, we’re on the right track for more biotech downside.

If LABD makes a new daily high … above yesterday’s LABD, 30.42, high, we have confirmation of a shake-out.

Right now, we’re still in the pre-market.

However, LABD is already trading up between +3.5% – +4.7%, which weighs probability to more upside … downside for SPBIO.

If SPBIO somehow makes a new daily high (LABD, new low), the bulls are gaining a foothold.

At this point, the Project Stimulus account remains unchanged (not advice, not a recommendation):

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Biotech Has Left The Station

11:01 a.m. EST

Early morning action confirms trend’s right side.

Massive downside potential for biotech SPBIO; upside for inverse, LABD.

Unless there’s some kind of unexpected reversal, LABD is showing its colors … huge upside potential.

As expected, LABD has completed its testing action previously discussed in these two updates; here and here.

At the minimum, we’ve got a right side LABD trend that if followed, will result in a doubling of current price near the end of this month or early next.

A trailing stop can be used which adheres to the (now confirmed) trend; not advice, not a recommendation.

If LABD really is in the channel shown, the top of the range even at this point, is around the 170-level; nearly 550%, from current price.

As always, anything can happen. For now, we’re sitting tight and letting price action dictate the next trading move.

The Project Stimulus account will need to get above the $2,000 level before margin is allowed (by the broker).

By that time, it may be a moot point; volatility could be too high for any kind of size increase.

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Biotech Channel

10:19 a.m. EST

Biotech’s on track for a sustained decline

Inverse fund LABD, major upside potential

It’s possible, after ‘Day 55’, LABD (above) attempted to negate the uptrend (pushing out of the right side) … only to find itself a few days later back in the channel.

Looking at the big picture, could or will LABD reach the upper channel line?

Is that possible?

After the experience with oil futures going negative (last year) the first time in market history, it should be obvious, anything can happen.

If LABD’s in the trading channel shown, we’re still in the early stages of the move.

Today, the expectation is for price action to reverse; coming back to close (or test) near the trend line around 23.90 – 24.30.

If it does and then gaps higher tomorrow (Friday), thus confirming the trend, it’s potentially the last stop for low risk positioning (not advice, not a recommendation).

Otherwise, with LABD up 7%, as of this post, we could already be off to the races.

The ‘project’ account is unchanged:

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Access Denied

11:12 a.m., EST:

Word’s out on the street.

In what may be just the tip, two links below are businesses denying access to those who have been injected.

Florida private school prohibits teacher access.

Physician’s message about denied access to services.

Here’s the catalyst discussion related to the above links.

Here’s a link to the PDF.

Note: The last two links do not verify the veracity of the referenced material. Be advised.

Momentum is building for some kind of ‘tipping point’.

We may be there now.

We’re looking for an avalanche of reports whose combined (fundamental and technical) effect is catastrophic implosion of the biotech sector.

Market Analysis:

The chart speaks for itself. It’s obvious biotech has reversed and could be in serious trouble.

The inverse fund LABD is up a stiff 10.5%, as of this post:

We may or may not have a trading channel as shown.

The right side trendline will need more confirmation. As always, anything can happen and the nascent move could fall apart.

However, what is known:

SPBIO’s (and LABD’s) pivot was called ‘to the day’.

The “Iceberg” notation references this report, where the probability of SPBIO downside at that juncture was presented.

That analysis was correct. SPBIO never looked back.

Positioning:

Our ‘project’ position remains open (not advice, not a recommendation). The correct stance under current circumstances is to let price action take LABD higher.

As Livermore said nearly a century ago, the hard part now is to ‘sit tight’. Let the market determine when the move has ended.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Iceberg … Dead Ahead

12:32 p.m. EST

Time and technical have come together; indicating potential downside collapse in biotech.

Collapse potential is immense and has been for years.

Fibonacci 55 days after the 2/10/21, highs, biotech (SPBIO), pivots decisively lower.

Of all the major indices, biotech on a percentage basis, is the downside leader.

Rightly so.

Fundamentally, it’s poised to disintegrate with its illegal, Mengele style campaign of medical experimentation.

Who knows if that full disclosure will happen.

The ‘controllers’, the oligarchs, may come up with some other mechanism to usurp the media, the internet and keep it all under wraps.

However, it looks like the tide’s turning.

Remember, the market leads the news; not the other way around.

If biotech goes into its well deserved collapse, downside action itself will be the catalyst for exposure.

For now, SPBIO is pivoting lower; LABD higher.

The daily chart of LABD shows the Fibonacci time relationship. From low to low; Fibonacci 55 days.

Yesterday, the 28th, was Day 55.

Today, LABD has already posted a new daily high … weighting probability to more upside (SPBIO, lower).

The next chart has the potential trading channel.

It looks aggressive.

However, the market itself has defined the trend.

Shown, in pervious updates, this trend angle has been repeated at least four times from March 5th, LABD high, to yesterday’s low.

It’s no guarantee. We’ll let subsequent price action confirm or negate the right side trend.

As of this post, LABD continues to push aggressively higher.

Our ‘project’ has an open position in LABD.

Without revealing specifics of that position (discussed previously), it’s represented in the table below:

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Last Gasp … Biotech?

3:42 p.m. EST:

Inverse fund LABD breaks out from a wedge pattern (to the downside) on reduced thrust energy.

Has this downside (upside for biotech SPBIO) reached exhaustion?

The 2-Hour chart above shows drastically reduced thrust (volume-price) energy to the downside. In addition, a wedge is typically the last formation at the end of a move.

Price action is the final arbiter. We won’t know if SPBIO will resume its downtrend (LABD higher) until there’s a definitive reversal.

Early action stopped out the ‘project’ position with a small profit as shown in the table:

We’re going to make changes on how the trades in the project are shown; more on that later.

Fundamentals:

The speck injection horror show continues with this 1-hour, 20-minute meeting of internationally acclaimed medical physicians.

You’ll never seem them on the mainstream.

The bottom line is those who have received the speck protection are a threat to the well-being of everyone else.

Some of the physicals have discussed potential action such as quarantine (or visual identification) of those who have received this so-called protection.

That’s right, it’s the people who have subjected themselves to the gene altering therapy that are now the potential threat.

Possible remedial actions are discussed. The video is a must see.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Biotech Shell Game

12:32 p.m. EST:

If we pretend like we’re doing something, maybe no one will notice the real plan.

That plan is and always has been, to cull the herd.

For the sake of distraction, the EU is suing a major biotech manufacturer for a botched rollout.

Going to the ZeroHedge site and looking at the comments, we have a segment of the population that’s fully awake. A typical comment below:

After listening to the Amandha Vollmer interview, it appears ‘the great awakening’ as she calls it, is gaining steam.

As a side note: The Canadian government has been unsuccessful in shutting her business down and/or imposing fines for violating ‘speck’ mandates.

Her business is open. Masks are forbidden at her office.

Therefore, it’s possible and it is being done.

When or if Reiner Fuellmich is able to bring actual (Nuremberg style) suits to blow the whole narrative wide open is unknown … but we do have this:

Human rights attorney, Leigh Dundas calls for censure, resignation, termination and jail time for members of California’s Orange County Board of Supervisors.

We can see it all gaining ground.

When or if this market finally breaks loose to the downside, one has to be mentally prepared for an implosion like no other.

Remember oil futures going negative? Enough said.

Market Analysis:

All of the above provides the backdrop for biotech.

It’s interesting (then again, not really) how this sector’s nascent bear market’s being ignored by the financial press.

Instead of a breakout to the downside (as expected), yesterday the sector SPBIO, decided to test the 23.6%, retrace area.

Today’s early session was spent testing (to the upside) the resistance area.

Price action is now tentatively reversing; about to head lower again.

The hourly chart of LABD (3X inverse SPBIO) shows yesterday’s exit (well past the stop) and re-entry of the short position; not advice, not a recommendation.

For reasons that may be covered later, the stop was not in the market at the time.

In addition, there was a trading platform lock-up (on the broker’s side) at exit and re-entry. A series of amateur-like errors all around.

It’s just a reminder to all; when the market turns lower in earnest, brokers and their trade platforms may (probably will) become inoperative.

The whole event resulted in a significant ding to our ‘project account’

How quickly can this recover … we’ll see.

Below, we have the hourly chart again … but noted with what looks like a nascent trend.

That trend line was copied and re-positioned over prior LABD moves.

Note how this market repeats its characteristics. This angle of trend line has happened three times in the past month.

We have all been here before …

Summary:

We’re back in position. The chart has been updated and the stop (now in the market, GTC) listed at 20.96 (above break-even):

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.